Ashley Gallagher, Editor

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.

Food is medicine is a framework of policy and behavioral interventions, improving population health through access to healthy foods to increase food and nutrition security.

Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

There are approximately 98 million individuals have prediabetes, but approximately only 15 million actually know they have prediabetes.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Presenters at the American Diabetes Association 84th Scientific Sessions analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

With improved technology and innovations for diabetes, it is essential for health care providers and health agencies to collaborate to combat rising rates of diabetes.

Investigators compared the reference products of adalimumab (Humira; AbbVie) and etanercept (Enbrel; Amgen) with biosimilar products.

Caution Patients Against the Use of Redness-Reducing Eye Drops.

Pharmacy Times will be at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida from June 21 to June 24, 2024.

Impaired glucose tolerance is a significant risk factor for developing diabetes.

V116 (Capvaxive; Merck) elicited higher immune responses than the comparator for the serotypes that are unique to the vaccine, according to studies submitted to the FDA.

Mim8 had a safe and well-tolerated profile, with no deaths or thrombotic events reported for patients with hemophilia A.

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

The new findings were presented as an oral presentation at the 2024 European Calcified Tissue Society Congress, held from May 25, 2024, to May 28, 2024.

Individuals with very low- to intermediate-risk myelodysplastic syndromes treated with luspatercept (Reblozyl; Bristol Myers Squibb) achieved improvements in hemoglobulin levels.

Elafibranor (Iqirvo; GENFIT) is a first-in-class, once daily oral peroxisome proliferator-activated receptor for the treatment of primary biliary cholangitis.

The 4-in-1 respiratory diagnostic test is either a single nasopharyngeal or anterior nasal swab that can confirm or rule out SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus with a single test.

Polyarticular juvenile idiopathic arthritis is a form of arthritis that affects multiple joints at one time.

To qualify for therapy, patients must be screened for type 1 diabetes islet autoantibodies when they are asymptomatic, which requires better education on screening opportunities.

Serotypes associated with V116 (Merck & Co. Inc.) had higher clinical and economic burden for individuals with invasive pneumococcal disease.

By improving health insurance coverage and cost of inhalers, such as out-of-pocket caps, access to care can be increased. Some companies are aiming to improve access by implementing price caps.

Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.

FKS518 (Fresenius Kabi) would be indicated for the treatment of osteoporosis in men and women, including glucocorticoid-induced osteoporosis and bone loss due to prostate or breast cancer.

For patients with a blood eosinophil count of 150 cells/µL or greater, tezepelumab had a significant reduction of approximately 37% in the rate of moderate or severe exacerbations.

Lisocabtagene maraleucel is being investigated for mantle cell lymphoma, relapsed or refractory (R/R) large B-cell lymphoma, and R/R follicular lymphoma.

Approximately 40% of caregivers make dosing errors when administering liquid medication to children.